Short answer
Tvardi Therapeutics, Inc. (TVRD) filed an 8-K current report with the SEC on July 30, 2026 reporting Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.2). Exhibits 99.1 and 99.2 furnished under Regulation FD.
Tvardi Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 7.01 · Regulation FD Disclosure
- Exhibits 99.1 and 99.2 furnished under Regulation FD
- Disclosure not deemed filed under Exchange Act Section 18
- Limited liability and incorporation-by-reference protections for the company
Item EX-99.1 · Exhibit EX-99.2
- TTI-109 selected for ulcerative colitis after Phase 1 healthy-volunteer study, establishing UC as the company’s lead development focus
- Immune-cell reductions reached 76% for Th17 subsets, 43% for Tfh subsets and 71% for B-cell subsets linked to UC pathology
- Planned moderate-to-severe UC trial targets 2027, pending IND clearance and additional funding
- Oral therapy addresses a $3 billion U.S. and $9 billion global UC market with clinical remission rates below 30% for approved therapies
- Key risks: Phase 1 findings are pharmacodynamic, not efficacy results; development depends on financing and regulatory clearance
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Tvardi Therapeutics, Inc. 8-K filings
Get the next TVRD 8-K as it lands
Follow TVRD for push alerts, or ask the research agent what this filing means.